We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Compared to Estimates, Pfizer (PFE) Q1 Earnings: A Look at Key Metrics
Read MoreHide Full Article
For the quarter ended March 2025, Pfizer (PFE - Free Report) reported revenue of $13.72 billion, down 7.8% over the same period last year. EPS came in at $0.92, compared to $0.82 in the year-ago quarter.
The reported revenue represents a surprise of -0.88% over the Zacks Consensus Estimate of $13.84 billion. With the consensus EPS estimate being $0.64, the EPS surprise was +43.75%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Oncology- Ibrance- United States: $659 million versus the three-analyst average estimate of $565.50 million. The reported number represents a year-over-year change of -3%.
Revenues- Primary Care- Eliquis alliance revenues and direct sales- United States: $1.30 billion versus $1.39 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -8.1% change.
Revenues- Specialty Care- Enbrel- Total International: $140 million versus the three-analyst average estimate of $132.28 million. The reported number represents a year-over-year change of -12%.
Revenues- Oncology- Ibrance- Total International: $318 million versus $333.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -15.2% change.
Revenues- Oncology- Ibrance- Worldwide: $977 million versus $898.97 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7.3% change.
Revenue- Specialty Care- Cibinqo: $58 million versus $71.20 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +38.1% change.
Revenues- Specialty Care- Xeljanz- Worldwide: $128 million compared to the $141.92 million average estimate based on three analysts. The reported number represents a change of -34% year over year.
Revenues- Oncology- Inlyta- Worldwide: $219 million compared to the $207.30 million average estimate based on three analysts. The reported number represents a change of -7.6% year over year.
Revenue- Specialty Care- Worldwide: $3.99 billion versus the three-analyst average estimate of $3.98 billion. The reported number represents a year-over-year change of +3.8%.
Revenue- Primary Care- Worldwide: $5.70 billion versus $5.82 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -21% change.
Revenues- Oncology- Xtandi alliance revenues- United States: $458 million versus $419.37 million estimated by three analysts on average.
Revenues- Oncology- Xtandi alliance revenues- Worldwide: $458 million compared to the $419.37 million average estimate based on three analysts.
Shares of Pfizer have returned -9% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Compared to Estimates, Pfizer (PFE) Q1 Earnings: A Look at Key Metrics
For the quarter ended March 2025, Pfizer (PFE - Free Report) reported revenue of $13.72 billion, down 7.8% over the same period last year. EPS came in at $0.92, compared to $0.82 in the year-ago quarter.
The reported revenue represents a surprise of -0.88% over the Zacks Consensus Estimate of $13.84 billion. With the consensus EPS estimate being $0.64, the EPS surprise was +43.75%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Oncology- Ibrance- United States: $659 million versus the three-analyst average estimate of $565.50 million. The reported number represents a year-over-year change of -3%.
- Revenues- Primary Care- Eliquis alliance revenues and direct sales- United States: $1.30 billion versus $1.39 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -8.1% change.
- Revenues- Specialty Care- Enbrel- Total International: $140 million versus the three-analyst average estimate of $132.28 million. The reported number represents a year-over-year change of -12%.
- Revenues- Oncology- Ibrance- Total International: $318 million versus $333.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -15.2% change.
- Revenues- Oncology- Ibrance- Worldwide: $977 million versus $898.97 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7.3% change.
- Revenue- Specialty Care- Cibinqo: $58 million versus $71.20 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +38.1% change.
- Revenues- Specialty Care- Xeljanz- Worldwide: $128 million compared to the $141.92 million average estimate based on three analysts. The reported number represents a change of -34% year over year.
- Revenues- Oncology- Inlyta- Worldwide: $219 million compared to the $207.30 million average estimate based on three analysts. The reported number represents a change of -7.6% year over year.
- Revenue- Specialty Care- Worldwide: $3.99 billion versus the three-analyst average estimate of $3.98 billion. The reported number represents a year-over-year change of +3.8%.
- Revenue- Primary Care- Worldwide: $5.70 billion versus $5.82 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -21% change.
- Revenues- Oncology- Xtandi alliance revenues- United States: $458 million versus $419.37 million estimated by three analysts on average.
- Revenues- Oncology- Xtandi alliance revenues- Worldwide: $458 million compared to the $419.37 million average estimate based on three analysts.
View all Key Company Metrics for Pfizer here>>>Shares of Pfizer have returned -9% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.